SCHEMBL25073302

SCHEMBL25073302

COc1cc(C(=O)O)ccc1NS(=O)(=O)c1csc(-c2ccc(F)cc2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.46
▸ MAPT P10636 5/20 0.46
▸ GAA P10253 1/20 0.46
▸ RAD52 P43351 1/20 0.44
▸ TP53 P04637 2/20 0.44
▸ ACLY P53396 4/20 0.43
▸ ALDH1A1 P00352 5/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ LMNA P02545 3/20 0.42
▸ HPGD P15428 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ ERAP1 Q9NZ08 1/20 0.42
▸ FABP4 P15090 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25072667 0.99 KDM4E (0.45) KDM4EMAPTGAARAD52TP53
SCHEMBL25073387 0.95 MAPT (0.43) KDM4EMAPTGAARAD52TP53
SCHEMBL25073709 0.95 MAPT (0.42) KDM4EMAPTGAARAD52TP53
SCHEMBL25073677 0.94 ACLY (0.46) KDM4EMAPTGAARAD52TP53
SCHEMBL25072899 0.94 KDM4E (0.48) KDM4EGAARAD52ACLYALDH1A1
SCHEMBL25073567 0.92 MAPT (0.46) KDM4EMAPTGAATP53ALDH1A1
SCHEMBL25073038 0.91 ACLY (0.44) KDM4EMAPTRAD52ACLYALDH1A1
SCHEMBL25072660 0.91 ACLY (0.53) KDM4ERAD52ACLYALDH1A1SMN1; SMN2
SCHEMBL25073279 0.91 ALDH1A1 (0.54) KDM4EMAPTRAD52ACLYALDH1A1
SCHEMBL25073260 0.91 ACLY (0.50) KDM4ERAD52ACLYALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed
WO-2023023310-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. (US) 2023-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF HSD17B1, HSD17B13, HSD17B3 KDM4E 2637/4885MAPT 3642/4885GAA 389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback